"The bull case argued: Theravance's substantial cash balance and near-certain milestone payment provide a floor for the stock, creating an asymmetric risk/reward setup."

"The thesis presented: Theravance's 35% economic interest in the COPD drug UPELRI is worth ~$525M in a DCF, representing the core value driver beyond cash."

"The guest argued the upcoming launch of UPELRI in China is an underappreciated catalyst that could add hundreds of millions in value to Theravance."

"The case made: The presence of two activists on the board and a concentrated shareholder base increases the likelihood of a successful strategic review and sale of the company."